Does sparsentan have any side effects in treating IgA nephropathy

Common side effects of sparsentane in the treatment of IgA nephropathy include swelling of the hands, legs, ankles, and feet (peripheral edema), dizziness, low red blood cells (anemia), hyperkalemia, hypotension (including orthostatic hypotension), acute kidney injury, and elevated transaminases.

Sparsentane treatment for IgA nephropathy may also cause serious side effects, including possible liver problems, severe birth defects, low blood pressure, worsening of kidney function, increased potassium in the blood, and fluid retention.

Tell your doctor right away if you develop any of the following signs of liver problems during treatment with sparsentane: nausea or vomiting, pain in the upper right side of your stomach, fatigue, loss of appetite, yellowing of the whites of the skin or eyes (jaundice), dark "tea-colored" urine, fever, itching.

Patients who are able to become pregnant must have a negative pregnancy test before starting and every month during treatment and for 1 month after stopping treatment with sparsentane.

You need to tell your doctor about all the patient's conditions before treatment with Sparsentan, including: high blood pressure or heart problems, liver problems; all medications the patient takes, including prescription and over-the-counter drugs, vitamins, herbal supplements, and grapefruit, NSAIDs

Potassium-containing medicines, potassium supplements or potassium-containing salt substitutes, antihypertensive drugs, etc.

Patients who develop symptoms suggestive of hepatotoxicity (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching) should immediately discontinue treatment with sparsentan and seek medical attention. If transaminase levels are abnormal at any time during treatment, interrupt sparsentane and monitor as recommended.

If hypotension occurs despite exclusion or reduction of other antihypertensive agents, consider a dose reduction or interruption of the sparsentane dose. Transient hypotensive reactions are not a contraindication to further administration of sparsentan, which may be administered after blood pressure has stabilized.

Consider withholding or discontinuing treatment in patients who experience a clinically significant decrease in renal function while receiving sparsentane.

Monitor serum potassium regularly and treat appropriately. Patients with end-stage renal disease or who are concurrently taking potassium-increasing drugs (e.g., potassium supplements, potassium-sparing diuretics) or using potassium-containing salt substitutes are at increased risk for developing hyperkalemia.

Recommended related articles: